Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology

Malik, 1989, Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M, Mol. Cell. Biol., 9, 2847, 10.1128/MCB.9.7.2847

Malik, 1995, Developmental abnormalities in mice transgenic for bovine oncostatin M, Mol. Cell. Biol., 15, 2349, 10.1128/MCB.15.5.2349

Yoshimura, 1996, Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway, EMBO J., 15, 1055, 10.1002/j.1460-2075.1996.tb00443.x

Okaya, 2005, Oncostatin M inhibits proliferation of rat oval cells OC15-5, inducing differentiation into hepatocytes, Am. J. Pathol., 166, 709, 10.1016/S0002-9440(10)62292-4

Giovannini, 1993, Tandem linkage of genes coding for leukemia inhibitory factor (LIF) and oncostatin M (OSM) on human chromosome 22, Cytogenet. Cell Genet., 64, 240, 10.1159/000133586

Jeffery, 1993, Close proximity of the genes for leukemia inhibitory factor and oncostatin M, Cytokine, 5, 107, 10.1016/1043-4666(93)90048-A

Ma, 1999, Cloning and characterization of human oncostatin M promoter, Nucleic Acids Res., 27, 4649, 10.1093/nar/27.23.4649

Berchtold, 1997, Cytokine receptor-independent, constitutively active variants of STAT5, J. Biol. Chem., 272, 30237, 10.1074/jbc.272.48.30237

Schwaller, 2000, Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2, Mol. Cell, 6, 693, 10.1016/S1097-2765(00)00067-8

Hoermann, 2012, Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms, FASEB J., 26, 894, 10.1096/fj.11-193078

1Repovic, 2002, Prostaglandin E2 is a novel inducer of oncostatin-M expression in macrophages and microglia, J. Neurosci., 22, 5334, 10.1523/JNEUROSCI.22-13-05334.2002

Henkel, 2011, Oncostatin M produced in Kupffer cells in response to PGE2: possible contributor to hepatic insulin resistance and steatosis, Lab. Invest., 91, 1107, 10.1038/labinvest.2011.47

Ganesh, 2012, Prostaglandin E(2) induces oncostatin M expression in human chronic wound macrophages through Axl receptor tyrosine kinase pathway, J. Immunol., 189, 2563, 10.4049/jimmunol.1102762

Guihard, 2012, Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling, Stem Cells, 30, 762, 10.1002/stem.1040

Zarling, 1986, Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells, Proc. Natl. Acad. Sci. U. S. A., 83, 9739, 10.1073/pnas.83.24.9739

Grenier, 2001, Oncostatin M production by blood and alveolar neutrophils during acute lung injury, Lab. Invest., 81, 133, 10.1038/labinvest.3780220

Suda, 2002, Oncostatin M production by human dendritic cells in response to bacterial products, Cytokine, 17, 335, 10.1006/cyto.2002.1023

Brown, 1987, Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells, J. Immunol., 139, 2977, 10.4049/jimmunol.139.9.2977

Queen, 2005, Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression, Cancer Res., 65, 8896, 10.1158/0008-5472.CAN-05-1734

Goren, 2006, Oncostatin M expression is functionally connected to neutrophils in the early inflammatory phase of skin repair: implications for normal and diabetes-impaired wounds, J. Invest. Dermatol., 126, 628, 10.1038/sj.jid.5700136

Sato, 2014, Oncostatin M maintains the hematopoietic microenvironment in the bone marrow by modulating adipogenesis and osteogenesis, PLoS ONE, 9, e116209, 10.1371/journal.pone.0116209

Neininger, 2002, MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels, J. Biol. Chem., 277, 3065, 10.1074/jbc.C100685200

Chen, 1995, AU-rich elements: characterization and importance in mRNA degradation, Trends Biochem. Sci., 20, 465, 10.1016/S0968-0004(00)89102-1

Bandyopadhyay, 2008, PMA induces stabilization of oncostatin M mRNA in human lymphoma U937 cells, Biochem. J., 410, 177, 10.1042/BJ20070311

Linsley, 1990, Cleavage of a hydrophilic C-terminal domain increases growth-inhibitory activity of oncostatin M, Mol. Cell. Biol., 10, 1882, 10.1128/MCB.10.5.1882

Hoffman, 1996, Resonance assignments for Oncostatin M, a 24-kDa alpha-helical protein, J. Biomol. NMR, 7, 273, 10.1007/BF00200429

Lindberg, 1998, Cloning and characterization of a specific receptor for mouse oncostatin M, Mol. Cell. Biol., 18, 3357, 10.1128/MCB.18.6.3357

Juan, 2009, Mice overexpressing murine oncostatin M (OSM) exhibit changes in hematopoietic and other organs that are distinct from those of mice overexpressing human OSM or bovine OSM, Vet. Pathol., 46, 124, 10.1354/vp.46-1-124

de Miguel, 1997, Ontogeny and localization of an oncostatin M-like protein in the rat testis: its possible role at the start of spermatogenesis, Cell Growth Differ., 8, 611

Nakayama, 1997, Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins, Biochem. J., 327, 625, 10.1042/bj3270625

Somasundaram, 2002, Interstitial collagens I, III, and VI sequester and modulate the multifunctional cytokine oncostatin M, J. Biol. Chem., 277, 3242, 10.1074/jbc.M110011200

Ryan, 2015, Oncostatin M binds to extracellular matrix in a bioactive conformation: implications for inflammation and metastasis, Cytokine, 72, 71, 10.1016/j.cyto.2014.11.007

Bamber, 1998, Oncostatin M stimulates excessive extracellular matrix accumulation in a transgenic mouse model of connective tissue disease, J. Mol. Med. (Berl), 76, 61, 10.1007/s109-1998-8105-3

Wong, 2014, Oncostatin M overexpression induces matrix deposition, STAT3 activation, and SMAD1 dysregulation in lungs of fibrosis-resistant BALB/c mice, Lab. Invest., 94, 1003, 10.1038/labinvest.2014.81

Gearing, 1992, The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor, Science, 255, 1434, 10.1126/science.1542794

Liu, 1992, Interleukin-6 signal transducer gp130 mediates oncostatin M signaling, J. Biol. Chem., 267, 16763, 10.1016/S0021-9258(18)41845-5

Sporeno, 1994, Oncostatin M binds directly to gp130 and behaves as interleukin-6 antagonist on a cell line expressing gp130 but lacking functional oncostatin M receptors, J. Biol. Chem., 269, 10991, 10.1016/S0021-9258(19)78081-8

Mosley, 1996, Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation, J. Biol. Chem., 271, 32635, 10.1074/jbc.271.51.32635

Dillon, 2004, Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice, Nat. Immunol., 5, 752, 10.1038/ni1084

Richards, 1997, Regulation of tissue inhibitor of metalloproteinase-1 in fibroblasts and acute phase proteins in hepatocytes in vitro by mouse oncostatin M, cardiotrophin-1, and IL-6, J. Immunol., 159, 2431, 10.4049/jimmunol.159.5.2431

Walker, 2010, Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice, J. Clin. Invest., 120, 582, 10.1172/JCI40568

Drechsler, 2012, Characterization of the rat oncostatin M receptor complex which resembles the human, but differs from the murine cytokine receptor, PLoS ONE, 7, e43155, 10.1371/journal.pone.0043155

Deller, 2000, Crystal structure and functional dissection of the cytostatic cytokine oncostatin M, Structure, 8, 863, 10.1016/S0969-2126(00)00176-3

Olivier, 2000, Identification of a gp130 cytokine receptor critical site involved in oncostatin M response, J. Biol. Chem., 275, 5648, 10.1074/jbc.275.8.5648

Plun-Favreau, 2003, Leukemia inhibitory factor (LIF), cardiotrophin-1, and oncostatin M share structural binding determinants in the immunoglobulin-like domain of LIF receptor, J. Biol. Chem., 278, 27169, 10.1074/jbc.M303168200

Kallen, 1999, Receptor recognition sites of cytokines are organized as exchangeable modules Transfer of the leukemia inhibitory factor receptor-binding site from ciliary neurotrophic factor to interleukin-6, J. Biol. Chem., 274, 11859, 10.1074/jbc.274.17.11859

Chollangi, 2012, A unique loop structure in oncostatin M determines binding affinity toward oncostatin M receptor and leukemia inhibitory factor receptor, J. Biol. Chem., 287, 32848, 10.1074/jbc.M112.387324

Taupin, 1999, Binding of leukemia inhibitory factor (LIF) to mutants of its low affinity receptor, gp190, reveals a LIF binding site outside and interactions between the two cytokine binding domains, J. Biol. Chem., 274, 14482, 10.1074/jbc.274.20.14482

Caffarel, 2014, Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma, J. Pathol., 232, 386, 10.1002/path.4305

West, 2012, Oncostatin M suppresses oestrogen receptor-alpha expression and is associated with poor outcome in human breast cancer, Endocr. Relat. Cancer, 19, 181, 10.1530/ERC-11-0326

Lacreusette, 2007, Loss of oncostatin M receptor beta in metastatic melanoma cells, Oncogene, 26, 881, 10.1038/sj.onc.1209844

Kim, 2009, Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer, PLoS ONE, 4, e6555, 10.1371/journal.pone.0006555

Arita, 2008, Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis, Am. J. Hum. Genet., 82, 73, 10.1016/j.ajhg.2007.09.002

Tanaka, 2009, New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis, Br. J. Dermatol., 161, 1217, 10.1111/j.1365-2133.2009.09311.x

Janssens, 2015, Oncostatin M protects against demyelination by inducing a protective microglial phenotype, Glia, 10.1002/glia.22840

Hsu, 2015, Analysis of IL-6/gp130 family receptor expression reveals that in contrast to astroglia, microglia lack the oncostatin M receptor and functional responses to oncostatin M, Glia, 63, 132, 10.1002/glia.22739

Blanchard, 2001, Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms, J. Biol. Chem., 276, 47038, 10.1074/jbc.M107971200

Chen, 2008, Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas, J. Pathol., 215, 290, 10.1002/path.2361

Diveu, 2006, Molecular and functional characterization of a soluble form of oncostatin M/interleukin-31 shared receptor, J. Biol. Chem., 281, 36673, 10.1074/jbc.M607005200

Kausar, 2011, Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma, Cell Oncol. (Dordr), 34, 177, 10.1007/s13402-011-0011-2

Gerhard, 2004, The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC), Genome Res., 14, 2121, 10.1101/gr.2596504

Heinrich, 1998, Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway, Biochem. J., 334, 297, 10.1042/bj3340297

Heinrich, 2003, Principles of interleukin (IL)-6-type cytokine signalling and its regulation, Biochem. J., 374, 1, 10.1042/bj20030407

Hermanns, 1999, Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130, J. Immunol., 163, 6651, 10.4049/jimmunol.163.12.6651

Haan, 2005, Multiple reasons for an inefficient STAT1 response upon IL-6-type cytokine stimulation, Cell. Signal., 17, 1542, 10.1016/j.cellsig.2005.03.010

Hintzen, 2008, Box 2 region of the oncostatin M receptor determines specificity for recruitment of Janus kinases and STAT5 activation, J. Biol. Chem., 283, 19465, 10.1074/jbc.M710157200

Guschin, 1995, A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6, EMBO J., 14, 1421, 10.1002/j.1460-2075.1995.tb07128.x

Auguste, 1997, Signaling of type II oncostatin M receptor, J. Biol. Chem., 272, 15760, 10.1074/jbc.272.25.15760

Radtke, 2002, Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression, J. Biol. Chem., 277, 11297, 10.1074/jbc.M100822200

Radtke, 2005, The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression, J. Biol. Chem., 280, 25760, 10.1074/jbc.M500822200

Radtke, 2006, Three dileucine-like motifs within the interbox1/2 region of the human oncostatin M receptor prevent efficient surface expression in the absence of an associated Janus kinase, J. Biol. Chem., 281, 4024, 10.1074/jbc.M511779200

Wang, 2000, Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor, J. Biol. Chem., 275, 25273, 10.1074/jbc.M002296200

Kuropatwinski, 1997, Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6, J. Biol. Chem., 272, 15135, 10.1074/jbc.272.24.15135

Stahl, 1995, Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors, Science, 267, 1349, 10.1126/science.7871433

Gerhartz, 1996, Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130 I. Definition of a novel phosphotyrosine motif mediating STAT1 activation, J. Biol. Chem., 271, 12991, 10.1074/jbc.271.22.12999

Snyder, 2011, Signal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration, J. Biol. Chem., 286, 38886, 10.1074/jbc.M111.286245

Fritz, 2006, Oncostatin-M up-regulates VCAM-1 and synergizes with IL-4 in eotaxin expression: involvement of STAT6, J. Immunol., 176, 4352, 10.4049/jimmunol.176.7.4352

Hermanns, 2000, Non-redundant signal transduction of interleukin-6-type cytokines The adapter protein Shc is specifically recruited to rhe oncostatin M receptor, J. Biol. Chem., 275, 40742, 10.1074/jbc.M005408200

Boing, 2006, Oncostatin M-induced activation of stress-activated MAP kinases depends on tyrosine 861 in the OSM receptor and requires Jak1 but not Src kinases, Cell. Signal., 18, 50, 10.1016/j.cellsig.2005.03.015

Underhill-Day, 2006, Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel, Cancer Res., 66, 10891, 10.1158/0008-5472.CAN-06-1766

Schnittker, 2013, Oncostatin M and TLR-4 ligand synergize to induce MCP-1 IL-6, and VEGF in human aortic adventitial fibroblasts and smooth muscle cells, Mediators Inflamm., 2013, 317503, 10.1155/2013/317503

Smyth, 2006, Oncostatin M-induced IL-6 expression in murine fibroblasts requires the activation of protein kinase Cdelta, J. Immunol., 177, 8740, 10.4049/jimmunol.177.12.8740

Smyth, 2015, Oncostatin M regulates osteogenic differentiation of murine adipose-derived mesenchymal progenitor cells through a PKCdelta-dependent mechanism, Cell Tissue Res., 360, 309, 10.1007/s00441-014-2099-y

Magrangeas, 2001, Negative regulation of onconstatin M signaling by suppressor of cytokine signaling (SOCS-3), Eur. Cytokine Netw., 12, 309

Komyod, 2007, Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line, Mol. Cancer Res., 5, 271, 10.1158/1541-7786.MCR-06-0274

Liu, 2014, Key role of suppressor of cytokine signaling 3 in regulating gp130 cytokine-induced signaling and limiting chondrocyte responses during murine inflammatory arthritis, Arthritis Rheumatol., 66, 2391, 10.1002/art.38701

Liu, 2015, Distinctive pro-inflammatory gene signatures induced in articular chondrocytes by oncostatin M and IL-6 are regulated by Suppressor of Cytokine Signaling-3, Osteoarthr. Cartil., 10.1016/j.joca.2015.05.011

Baker, 2008, Molecular basis of oncostatin M-induced SOCS-3 expression in astrocytes, Glia, 56, 1250, 10.1002/glia.20694

Ehlting, 2015, Oncostatin M regulates SOCS3 mRNA stability via the MEK-ERK1/2-pathway independent of p38(MAPK)/MK2, Cell. Signal., 27, 555, 10.1016/j.cellsig.2014.12.016

Stross, 2006, Oncostatin M receptor-mediated signal transduction is negatively regulated by SOCS3 through a receptor tyrosine-independent mechanism, J. Biol. Chem., 281, 8458, 10.1074/jbc.M511212200

Richards, 2013, The enigmatic cytokine oncostatin m and roles in disease, ISRN Inflamm., 2013, 512103, 10.1155/2013/512103

Demyanets, 2012, Vascular effects of glycoprotein130 ligands—Part I: Pathophysiological role, Vascul. Pharmacol., 56, 34, 10.1016/j.vph.2011.12.004

Demyanets, 2012, Vascular effects of glycoprotein130 ligands—Part II: Biomarkers and therapeutic targets, Vascul. Pharmacol., 57, 29, 10.1016/j.vph.2011.12.007

Sims, 2014, Osteoimmunology: oncostatin M as a pleiotropic regulator of bone formation and resorption in health and disease, Bonekey Rep., 3, 527, 10.1038/bonekey.2014.22

Szibor, 2014, Remodeling and dedifferentiation of adult cardiomyocytes during disease and regeneration, Cell. Mol. Life Sci., 71, 1907, 10.1007/s00018-013-1535-6

Elks, 2015, Oncostatin m modulation of lipid storage, Biology (Basel), 4, 151

Morikawa, 2004, Essential function of oncostatin m in nociceptive neurons of dorsal root ganglia, J. Neurosci., 24, 1941, 10.1523/JNEUROSCI.4975-03.2004

Tanaka, 2003, Targeted disruption of oncostatin M receptor results in altered hematopoiesis, Blood, 102, 3154, 10.1182/blood-2003-02-0367

Minehata, 2006, Oncostatin m maintains the hematopoietic microenvironment and retains hematopoietic progenitors in the bone marrow, Int. J. Hematol., 84, 319, 10.1532/IJH97.06090

Mukouyama, 1998, In vitro expansion of murine multipotential hematopoietic progenitors from the embryonic aorta-gonad-mesonephros region, Immunity, 8, 105, 10.1016/S1074-7613(00)80463-X

Miyajima, 2000, Role of Oncostatin M in hematopoiesis and liver development, Cytokine Growth Factor Rev., 11, 177, 10.1016/S1359-6101(00)00003-4

Lee, 2007, Oncostatin M stimulates expression of stromal-derived factor-1 in human mesenchymal stem cells, Int. J. Biochem. Cell Biol., 39, 650, 10.1016/j.biocel.2006.11.003

Albiero, 2015, Bone marrow macrophages contribute to diabetic stem cell mobilopathy by producing Oncostatin M, Diabetes, 10.2337/db14-1473

Miyaoka, 2006, Oncostatin M inhibits adipogenesis through the RAS/ERK and STAT5 signaling pathways, J. Biol. Chem., 281, 37913, 10.1074/jbc.M606089200

Song, 2007, Oncostatin M decreases adiponectin expression and induces dedifferentiation of adipocytes by JAK3- and MEK-dependent pathways, Int. J. Biochem. Cell Biol., 39, 439, 10.1016/j.biocel.2006.07.014

Morikawa, 2009, Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow, J. Exp. Med., 206, 2483, 10.1084/jem.20091046

Nawa, 2013, Discovering small molecules that inhibit adipogenesis and promote osteoblastogenesis: unique screening and Oncostatin M-like activity, Differentiation, 86, 65, 10.1016/j.diff.2013.07.005

Walker, 2012, Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo, J. Bone Miner. Res., 27, 902, 10.1002/jbmr.1506

Komori, 2013, Lack of oncostatin M receptor beta leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype, J. Biol. Chem., 288, 21861, 10.1074/jbc.M113.461905

Komori, 2014, Deficiency of oncostatin M receptor beta (OSMRbeta) exacerbates high-fat diet-induced obesity and related metabolic disorders in mice, J. Biol. Chem., 289, 13821, 10.1074/jbc.M113.542399

Komori, 2015, Oncostatin M is a potential agent for the treatment of obesity and related metabolic disorders: a study in mice, Diabetologia, 10.1007/s00125-015-3613-9

Nakamura, 2004, Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice, Hepatology, 39, 635, 10.1002/hep.20086

Hamada, 2007, Oncostatin M gene therapy attenuates liver damage induced by dimethylnitrosamine in rats, Am. J. Pathol., 171, 872, 10.2353/ajpath.2007.060972

Kubin, 2011, Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling, Cell Stem Cell, 9, 420, 10.1016/j.stem.2011.08.013

Sun, 2015, Oncostatin M (OSM) protects against cardiac ischaemia/reperfusion injury in diabetic mice by regulating apoptosis, mitochondrial biogenesis and insulin sensitivity, J. Cell. Mol. Med., 19, 1296, 10.1111/jcmm.12501

Poling, 2014, Therapeutic targeting of the oncostatin M receptor-beta prevents inflammatory heart failure, Basic Res. Cardiol., 109, 396, 10.1007/s00395-013-0396-3

Lorchner, 2015, Myocardial healing requires Reg3beta-dependent accumulation of macrophages in the ischemic heart, Nat. Med., 21, 353, 10.1038/nm.3816

Hams, 2008, Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation, J. Immunol., 181, 2174, 10.4049/jimmunol.181.3.2174

Ishii, 2009, Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders, Blood, 113, 5942, 10.1182/blood-2008-09-179416

Niyonsaba, 2010, Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells, J. Immunol., 184, 3526, 10.4049/jimmunol.0900712

Cornelissen, 2011, Ultraviolet B radiation and reactive oxygen species modulate interleukin-31 expression in T lymphocytes, monocytes and dendritic cells, Br. J. Dermatol., 165, 966, 10.1111/j.1365-2133.2011.10487.x

Mizuno, 2009, Molecular cloning of canine interleukin-31 and its expression in various tissues, Vet. Immunol. Immunopathol., 131, 140, 10.1016/j.vetimm.2009.03.014

Zhang, 2008, Structures and biological functions of IL-31 and IL-31 receptors, Cytokine Growth Factor Rev., 19, 347, 10.1016/j.cytogfr.2008.08.003

Cornelissen, 2012, Signaling by IL-31 and functional consequences, Eur. J. Cell Biol., 91, 552, 10.1016/j.ejcb.2011.07.006

Park, 2012, Transcriptional activation of the IL31 gene by NFAT and STAT6, J. Leukoc. Biol., 91, 245, 10.1189/jlb.0111020

Maier, 2014, Human Th2 but not Th9 cells release IL-31 in a STAT6/NF-kappaB-dependent way, J. Immunol., 193, 645, 10.4049/jimmunol.1301836

Hwang, 2015, NFAT1 and JunB cooperatively regulate IL-31 gene expression in CD4+ T cells in health and disease, J. Immunol., 194, 1963, 10.4049/jimmunol.1401862

Stott, 2013, Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation, J. Allergy Clin. Immunol., 132, 446, 10.1016/j.jaci.2013.03.050

Le Saux, 2010, Molecular dissection of human interleukin-31-mediated signal transduction through site-directed mutagenesis, J. Biol. Chem., 285, 3470, 10.1074/jbc.M109.049189

Ghilardi, 2002, A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5, J. Biol. Chem., 277, 16831, 10.1074/jbc.M201140200

Diveu, 2003, GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor, J. Biol. Chem., 278, 49850, 10.1074/jbc.M307286200

Diveu, 2004, Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling, Eur. Cytokine Netw., 15, 291

Cevikbas, 2014, A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1, J. Allergy Clin. Immunol., 133, 448, 10.1016/j.jaci.2013.10.048

Ferretti, 2015, The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma, Leukemia, 29, 958, 10.1038/leu.2014.291

Jawa, 2008, Regulated expression of the IL-31 receptor in bronchial and alveolar epithelial cells, pulmonary fibroblasts, and pulmonary macrophages, J. Interferon Cytokine Res., 28, 207, 10.1089/jir.2007.0057

Heise, 2009, IL-31 receptor alpha expression in epidermal keratinocytes is modulated by cell differentiation and interferon gamma, J. Invest. Dermatol., 129, 240, 10.1038/jid.2008.183

Kasraie, 2011, Functional effects of interleukin 31 in human primary keratinocytes, Allergy, 66, 845, 10.1111/j.1398-9995.2011.02545.x

Horejs-Hoeck, 2012, Dendritic cells activated by IFN-gamma/STAT1 express IL-31 receptor and release proinflammatory mediators upon IL-31 treatment, J. Immunol., 188, 5319, 10.4049/jimmunol.1101044

Edukulla, 2015, Th2 cytokines augment IL-31/IL-31RA interactions via STAT6-dependent IL-31RA expression, J. Biol. Chem., 290, 13510, 10.1074/jbc.M114.622126

Bando, 2006, Complete overlap of interleukin-31 receptor A and oncostatin M receptor beta in the adult dorsal root ganglia with distinct developmental expression patterns, Neuroscience, 142, 1263, 10.1016/j.neuroscience.2006.07.009

Arai, 2015, Repeated administration of IL-31 upregulates IL-31 receptor A (IL-31RA) in dorsal root ganglia and causes severe itch-associated scratching behaviour in mice, Exp. Dermatol., 24, 75, 10.1111/exd.12587

Dreuw, 2004, Characterization of the signaling capacities of the novel gp130-like cytokine receptor, J. Biol. Chem., 279, 36112, 10.1074/jbc.M401122200

Chattopadhyay, 2007, Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells, J. Biol. Chem., 282, 3014, 10.1074/jbc.M609655200

Dambacher, 2007, Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease, Gut, 56, 1257, 10.1136/gut.2006.118679

Lee, 2012, Mechanistic correlations between two itch biomarkers, cytokine interleukin-31 and neuropeptide beta-endorphin, via STAT3/calcium axis in atopic dermatitis, Br. J. Dermatol., 167, 794, 10.1111/j.1365-2133.2012.11047.x

Schmitz, 2000, SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130, J. Biol. Chem., 275, 12848, 10.1074/jbc.275.17.12848

Bilsborough, 2006, IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis, J. Allergy Clin. Immunol., 117, 418, 10.1016/j.jaci.2005.10.046

Neis, 2006, Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis, J. Allergy Clin. Immunol., 118, 930, 10.1016/j.jaci.2006.07.015

Sonkoly, 2006, IL-31: a new link between T cells and pruritus in atopic skin inflammation, J. Allergy Clin. Immunol., 117, 411, 10.1016/j.jaci.2005.10.033

Lei, 2008, SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma, Allergy, 63, 327, 10.1111/j.1398-9995.2007.01566.x

Okano, 2011, Characterization of pollen antigen-induced IL-31 production by PBMCs in patients with allergic rhinitis, J. Allergy Clin. Immunol., 127, 277, 10.1016/j.jaci.2010.09.029

Liu, 2015, Interleukin-31 promotes helper T cell type-2 inflammation in children with allergic rhinitis, Pediatr. Res., 77, 20, 10.1038/pr.2014.151

Singer, 2013, IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus, J. Invest. Dermatol., 133, 2783, 10.1038/jid.2013.227

Rabenhorst, 2014, Interleukin-31: a novel diagnostic marker of allergic diseases, Curr. Allergy Asthma Rep., 14, 423, 10.1007/s11882-014-0423-y

Arai, 2013, A single dose of interleukin-31 (IL-31) causes continuous itch-associated scratching behaviour in mice, Exp. Dermatol., 22, 669, 10.1111/exd.12222

Hawro, 2014, Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge, Allergy, 69, 113, 10.1111/all.12316

Broxmeyer, 2007, Regulation of myeloid progenitor cell proliferation/survival by IL-31 receptor and IL-31, Exp. Hematol., 35, 78, 10.1016/j.exphem.2007.01.028

Perrigoue, 2007, IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung, J. Exp. Med., 204, 481, 10.1084/jem.20061791

Perrigoue, 2009, IL-31-IL-31R interactions limit the magnitude of Th2 cytokine-dependent immunity and inflammation following intestinal helminth infection, J. Immunol., 182, 6088, 10.4049/jimmunol.0802459

Kasraie, 2013, Interleukin (IL)-31 activates signal transducer and activator of transcription (STAT)-1 STAT-5 and extracellular signal-regulated kinase 1/2 and down-regulates IL-12p40 production in activated human macrophages, Allergy, 68, 739, 10.1111/all.12152

Bilsborough, 2010, IL-31 receptor (IL-31RA) knockout mice exhibit elevated responsiveness to oncostatin M, J. Immunol., 185, 6023, 10.4049/jimmunol.0902769

Economides, 2003, Cytokine traps: multi-component, high-affinity blockers of cytokine action, Nat. Med., 9, 47, 10.1038/nm811

Ancey, 2003, A fusion protein of the gp130 and interleukin-6Ralpha ligand-binding domains acts as a potent interleukin-6 inhibitor, J. Biol. Chem., 278, 16968, 10.1074/jbc.C300081200

Venereau, 2010, Definition and characterization of an inhibitor for interleukin-31, J. Biol. Chem., 285, 14955, 10.1074/jbc.M109.049163

Grimstad, 2009, Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis, Exp. Dermatol., 18, 35, 10.1111/j.1600-0625.2008.00766.x

Kasutani, 2014, Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice, Br. J. Pharmacol., 171, 5049, 10.1111/bph.12823

Boyman, 2015, EAACI IG biologicals task force paper on the use of biologic agents in allergic disorders, Allergy, 10.1111/all.12616